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Aims Cardiovascular (CV) hospitalization is a predictor of CV mortality and has a negative impact on patients’ quality of life.
TheprimaryendpointofAplacebo-controlled,double-blind,parallel-armTrialtoassesstheefﬁcacyofdronedarone400
mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENTs with Atrial ﬁbrillation/
atrial ﬂutter (ATHENA), a composite of ﬁrst CV hospitalization or death from any cause, was signiﬁcantly reduced by
dronedarone. This post hoc analysis evaluated the secondary endpoint of CV hospitalization and the clinical beneﬁt of
dronedarone on the number and duration of CV hospitalizations in patients with atrial ﬁbrillation (AF).
Methods
and results
ATHENA was a double-blind, parallel group study in 4628 patients with a history of paroxysmal/persistent AF and
additional risk factors, treated with placebo or dronedarone. Dronedarone treatment signiﬁcantly reduced the
risk of ﬁrst CV hospitalization (P , 0.0001 vs. placebo), while the risk of ﬁrst non-CV hospitalization was similar
in both groups (P ¼ 0.77). About half of the CV hospitalizations were AF-related, with a median duration of hospital
stay of four nights. The risk of any hospitalization for AF [hazard ratio (95% conﬁdence interval) 0.626
(0.54620.719)] and duration of hospital stay were signiﬁcantly reduced by dronedarone (P , 0.0001 vs. placebo).
Dronedarone treatment reduced total hospitalizations for acute coronary syndrome (P ¼ 0.0105) and the time
between the ﬁrst AF/atrial ﬂutter recurrence and CV hospitalization/death (P ¼ 0.0048). Hospitalization burden
was signiﬁcantly reduced across all levels of care (P , 0.05). Cumulative incidence data indicated that the effects
of dronedarone persisted for at least 24 months.
Conclusion Dronedarone reduced the risk for CV hospitalization and the total hospitalization burden in this patient group.
The trial is registered under ClinicalTrials.gov #NCT 00174785.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
The lifetime risk of atrial ﬁbrillation (AF) in men and women aged
40 years is one in four.
1 The incidence and prevalence of AF
increase with age, resulting in a substantial public health burden.
2
A community-based cohort study indicated a rise in AF of 13%
over the last 2 decades, and if this increase continues, 15.9
million people in the USA will develop AF by the year 2050.
2
The increasing occurrence of AF is associated with an increase in
mortality,
3,4 as well as debilitating stroke
5 and heart failure.
3,4
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doi:10.1093/europace/eur102Not unexpectedly, these trends are also associated with increased
hospitalizations related to AF,
6–9 which may, in turn, indicate
increased mortality risk.
10
In the recent ATHENA [A placebo-controlled, double-blind, par-
allel-arm Trial to assess the efﬁcacy of dronedarone 400 mg twice a
day (bid) for the prevention of cardiovascular Hospitalization or
death from any cause in patiENts with Atrial ﬁbrillation/atrial
ﬂutter] trial, in 4628 patients with paroxysmal or persistent AF or
atrial ﬂutter (AFL), dronedarone treatment signiﬁcantly decreased
the number of ﬁrst cardiovascular (CV) hospitalizations compared
with placebo [hazard ratio (HR) ¼ 0.74, P , 0.001], driven mainly
by a reduction in the number of hospitalizations for AF.
11 Further-
more, results from ATHENA demonstrated that dronedarone treat-
ment increases the time to ﬁrst hospitalization for CV reasons.
Here we present the results of a post hoc analysis, using data
from the ATHENA study to further evaluate the effect of drone-
darone on hospitalizations, by examining all hospitalization events
and the length of hospital stay in patients with paroxysmal or per-
sistent AF, or AFL.
Methods
Details of the main study protocol have been published previously.
11,12
In brief, ATHENA was a randomized, double-blind, placebo-controlled
trial conducted in 551 centres in 37 countries. The study was
conducted according to the principles of good clinical practice. Patients
were recruited between 29 June 2005 and 30 December 2006; sub-
jects were followed up for a minimum of 1 year. The trial was spon-
sored by sanoﬁ-aventis.
The aim of this post hoc data analysis was to evaluate the number of
ﬁrst hospitalizations per treatment group, the number of hospitaliz-
ations after ﬁrst AF/AFL recurrence, the number of all hospitalizations,
the duration of hospital stay, and the hospitalization burden over time.
Patient population
Patients with paroxysmal or persistent AF, or AFL, were eligible for
enrollment if one or more of the following risk factors were
present: aged ≥70 years, arterial hypertension (ongoing therapy with
at least two antihypertensive drugs of different classes), diabetes mel-
litus, prior stroke or transient ischaemic attack (TIA) or systemic
embolism, left atrial diameter ≥50 mm by M-mode echocardiography,
or left ventricular ejection fraction ≤40%. For each patient, a 12-lead
electrocardiogram (ECG) within 6 months prior to randomization had
to be available showing AF or AFL. A second 12-lead ECG within the
same period had to show sinus rhythm. During the course of the trial,
the inclusion criteria were revised, requiring patients to be aged ≥70
years with one or more of the pre-speciﬁed risk factors, or aged ≥75
years regardless of whether they had any previously speciﬁed risk
factors.
Exclusion criteria of note for this analysis included a diagnosis of
permanent AF, an unstable haemodynamic condition, NYHA class IV
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Table 1 Number of events and hazard ratio of ﬁrst hospitalization according to pre-speciﬁed reasons during the
on-study period
Reason for hospitalization Placebo
(n 5 2327)
Dronedarone
(n 5 2301)
HR (95% CI) Log-rank test
P value
CV hospitalizations
AF and other supraventricular rhythm disorders 510 335 0.626 (0.546–0.719) ,0.0001
Worsening CHF, including pulmonary oedema or dyspnoea
of cardiac origin
132 112 0.855 (0.665–1.100) 0.2207
Acute coronary syndrome
a 89 62 0.699 (0.506–0.967) 0.0296
Implantation of a pacemaker, implantable cardioverter
deﬁbrillator, or other cardiac device
81 64 0.793 (0.572–1.101) 0.1655
Stable angina pectoris or atypical chest pain 63 56 0.898 (0.626–1.287) 0.5561
TIA or stroke (except for intracranial haemorrhage) 61 43 0.708 (0.480–1.047) 0.0819
Transcutaneous coronary, cerebrovascular, or peripheral
procedure
48 44 0.925 (0.615–1.393) 0.7102
CV surgery except for cardiac transplantation 43 35 0.820 (0.525–1.281) 0.3824
Hypotension, hypertension; except for syncope 38 30 0.797 (0.494–1.286) 0.3509
Major bleeding (requiring two or more units of blood or any
intracranial haemorrhage)
33 36 1.103 (0.688–1.769) 0.6839
Syncope 32 27 0.853 (0.511–1.424) 0.5418
Atherosclerosis related (if not otherwise speciﬁed) 14 16 1.151 (0.562–2.358) 0.7004
Ventricular arrhythmia or non-fatal cardiac arrest 12 13 1.091 (0.498–2.391) 0.8277
Pulmonary embolism or deep vein thrombosis 6 14 2.337 (0.898–6.082) 0.0730
Ventricular extrasystoles 1 1 1.007 (0.063–16.106) 0.9958
Cardiac transplantation 1 0 NC NC
CV infection 0 4 NC NC
Non-CV hospitalizations 533 516 0.982 (0.870–1.108) 0.7688
NC, not calculable.
aAcute coronary syndrome includes myocardial infarction or unstable angina.
Effect of dronedarone on hospitalizations 1119congestive heart failure, any severe non-cardiac illness limiting life
expectancy, and conditions incompatible with inclusion in a clinical
trial.
Patients were randomly assigned to receive dronedarone 400 mg
bid or placebo (ratio 1:1). Randomization was stratiﬁed by centre
and by the presence or absence of AF or AFL at the time of
randomization.
The follow-up visit schedule included clinical evaluations at days
7 and 14, and at months 1, 3, 6, 9, 12, and every 3 months thereafter.
It was planned for the trial to have a minimum follow-up duration of 12
months and all patients, irrespective of the occurrence of a primary
endpoint, were followed until the common study end date of 30
December 2007 or until death, with the exception of two patients
in the placebo group who were lost to follow-up.
Reporting of hospitalizations
Any unplanned hospitalization (i.e. admission with an overnight stay in
hospital covering at least two consecutive dates) was categorized by
the investigator as either CV or non-CV according to pre-speciﬁed
main reasons.
12 The reasons for CV hospitalizations were deﬁned
prior to study start as follows: myocardial infarction or unstable
angina; stable angina pectoris or atypical chest pain; atherosclerosis
related (if not otherwise speciﬁed); transcutaneous coronary, cerebro-
vascular, or peripheral procedure; CV surgery except for cardiac trans-
plantation; AF and other supraventricular rhythm disorders; ventricular
arrhythmia or non-fatal cardiac arrest; worsening congestive heart
failure (CHF), including pulmonary oedema, or dyspnoea of cardiac
origin; cardiac transplantation; syncope; implantation of a pacemaker,
implantable cardioverter deﬁbrillator, or any other cardiac device;
TIA or stroke (except for intracranial haemorrhage); pulmonary embo-
lism or deep vein thrombosis; blood pressure related (hypotension or
hypertension; except for syncope); major bleeding (requiring two or
more units of blood or any intracranial haemorrhage); and CV infec-
tion. For each hospitalization, the number of nights spent in the hospi-
tal was recorded according to the following three categories: intensive
care unit or coronary care unit, step-down or medium care unit, and
regular ward.
Data for the primary endpoint and for CV hospitalizations separately
were also analysed for the following regions: North America, South
America, Eastern Europe, Western Europe, Asia, and ‘Other’ (compris-
ing Australia, India, Israel, Morocco, New Zealand, South Africa, and
Tunisia).
Statistical analysis
All analyses were performed according to the intention-to-treat prin-
ciple. A separate analysis was performed for each reason for a CV hos-
pitalization. Time to ﬁrst event was estimated using the Kaplan–Meier
method and compared by means of the log-rank test. All P values were
two tailed. The dronedarone-to-placebo HRs with conﬁdence intervals
(CIs) were estimated using Cox’s proportional hazard model.
Figure 1 Kaplan–Meier cumulative incidence curves of time from randomization to ﬁrst hospitalization for the intention-to-treat population.
(A) Cardiovascular hospitalization; (B) non-cardiovascular hospitalization; (C) hospitalization for atrial ﬁbrillation and other supraventricular dis-
orders; (D) non-atrial ﬁbrillation/atrial ﬂutter hospitalization.
C. Torp-Pedersen et al. 1120Time for all hospitalizations (CV/non-CV) was analysed by plotting
the mean number of CV/non-CV hospitalizations over time using
Nelson–Aalen non-parametric cumulative incidence functions for
each treatment group. The two treatment groups were compared
using a two-sided log-rank asymptotic test for repeated event-time
data. The HR and associated 95% CIs were estimated within the
Andersen–Gill multiplicative intensity regression with treatment
group as the only binary variable. The cumulative incidence was
described at selected time points (6 months, 12 months, 18 months,
24 months, and 30 months) according to the treatment group and
CV hospitalization status, and cumulative incidence for each 6-month
period (0–6 months, 6–12 months, 12–18 months, 18–24 months,
and 24–30 months) was derived.
The total number of hospitalizations and the number of total hospi-
talization days were compared using a log-rank test and a Wilcoxon
test, respectively.
Results
The ATHENA study enrolled 4628 patients, of whom 2301 were
assigned to dronedarone and 2327 to placebo. Patients had a
mean age of 71.6 years and included slightly more male than
female patients (53 and 47%, respectively); baseline characteristics
were similar between treatment groups.
11 As previously reported,
the mean+standard deviation follow-up duration for all patients
was 21+5 months, with a median of 22 months.
11 The
minimum follow-up duration was 1 year, and the maximum was
2.5 years. Details of adverse events occurring during the
ATHENA trial have been reported previously.
11
Overall, the number of ﬁrst CV hospitalizations was signiﬁcantly
decreased in the dronedarone group compared with placebo [675
patients in the dronedarone group vs. 859 in the placebo group
(HR ¼ 0.74, 95% CI, 0.67–0.82, P , 0.001)]. The number of ﬁrst
hospitalizations for each reason is shown in Table 1, evaluated by
the treatment group. The number of ﬁrst non-CV hospitalizations
is also shown. Among the ﬁrst CV hospitalizations, those related to
AF and acute coronary syndrome were signiﬁcantly fewer in the
dronedarone group compared with the placebo group (335 vs.
510, P , 0.0001 for AF, and 62 vs. 89, P ¼ 0.03 for acute coronary
syndrome, respectively). The numbers of hospitalizations for
stroke or TIA and for heart failure were non-signiﬁcantly
reduced: dronedarone 43 stroke/TIA hospitalizations vs. placebo
61 (P ¼ 0.08) and dronedarone 112 heart failure hospitalizations
......................................................... ..........................................................
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Table 2 Total number of hospitalizations and hospital days by pre-speciﬁed classiﬁcation
Total number of hospitalizations Total number of hospital days
Reason for hospitalization Placebo
(n 5 2327)
Dronedarone
(n 5 2301)
Log-rank test
P value
Placebo
(n 5 2327)
Dronedarone
(n 5 2301)
Wilcoxon test
P value
CV hospitalizations
AF and other supraventricular rhythm disorders 829 514 ,0.0001 4637 3132 ,0.0001
Worsening CHF, including pulmonary oedema or
dysponea of cardiac origin
184 165 0.505 1511 1486 0.202
Acute coronary syndrome
a 113 71 0.01047 1188 816 0.038
Implantation of a pacemaker, implantable
cardioverter deﬁbrillator, or other cardiac
device
83 65 NC 372 334 0.206
Stable angina pectoris or atypical chest pain 72 69 NC 533 402 0.611
TIA or stroke (except intracranial haemorrhage) 64 46 NC 1122 439 0.079
Transcutaneous coronary, cerebrovascular, or
peripheral procedure
55 52 NC 165 168 0.718
CV surgery except cardiac transplantation 47 38 NC 436 332 0.519
Hypotension, hypertension; except syncope 40 30 NC 297 238 0.349
Major bleeding (requiring two or more units of
blood or any intracranial haemorrhage)
33 41 NC 349 423 0.687
Syncope 33 32 NC 190 102 0.371
Atherosclerosis related (if not otherwise
speciﬁed)
20 17 NC 269 199 0.693
Ventricular arrhythmia or non-fatal cardiac arrest 14 16 NC 120 91 0.820
Pulmonary embolism or deep vein thrombosis 6 15 NC 121 137 0.070
Ventricular extrasystoles 1 1 NC 13 3 0.994
Cardiac transplantation 1 0 NC 20 0 0.320
CV infection 0 5 NC 0 14 0.044
Other CV hospitalization 285 254 0.2842 1870 1524 0.240
Non-CV hospitalizations 715 676 0.480 6326 5901 0.703
NC, not calculable.
aAcute coronary syndrome includes myocardial infarction or unstable angina.
Effect of dronedarone on hospitalizations 1121vs. placebo 132 (P ¼ 0.22). There was no difference between the
number of ﬁrst non-CV hospitalizations between groups (drone-
darone 516, placebo 533; P ¼ 0.77).
Figure 1 shows Kaplan–Meier curves of time to ﬁrst CV hospi-
talization events and non-CV hospitalization events, as well as time
to ﬁrst AF-related hospitalizations and ﬁrst non-AF-related
hospitalizations.
Overall, almost a quarter of the patients in each group had .1
hospitalization due to any cause during the study period (drone-
darone 20.1%, placebo 24.5%). Multiple CV hospitalizations were
reported in 12.3% of dronedarone-treated patients, and 15.9% in
the placebo group. Table 2 shows the number of hospitalizations
and their duration when all hospitalizations are included in the ana-
lyses, regardless of how many hospitalizations each patient had.
Among the patients experiencing at least one AF-related hospital-
ization during the study, 50% remained in hospital for at least four
nights and 25% for at least eight nights. The total number of hos-
pitalizations for AF was reduced from 829 with placebo to 514
(P , 0.001) with dronedarone and the number of days in hospital
from 4637 to 3132, respectively (P , 0.001). The number of hos-
pitalizations for acute coronary syndrome was reduced from 113 in
the placebo group to 71 in the dronedarone group (P ¼ 0.01) and
the number of hospitalization days from 1188 to 816, respectively
(P ¼ 0.04). Neither the total number nor the duration of non-CV
hospitalizations was reduced signiﬁcantly by dronedarone.
In Table 3, it can be seen that a reduction in the total number of
nights spent in hospital is observed at all levels of care. In addition,
dronedarone decreased the risk of ﬁrst CV hospitalization in the
intensive care unit or cardiological care unit by  19% compared
with placebo (Table 4). This reduction in risk was not only
observed in hospitalizations due to AF (placebo 122 vs. dronedar-
one 82), but also in hospitalizations due to stroke/TIA (21 vs. 11)
and myocardial infarction/unstable angina (31 vs. 24), indicating a
beneﬁcial effect of dronedarone beyond AF-related
hospitalizations.
Figure 2 shows the time from ﬁrst AF/AFL recurrence (based
on ECGs and cardioversion) to ﬁrst CV hospitalization or
death from any cause during the on-study period. This analysis
includes all randomized patients with a ﬁrst AF/AFL recurrence
(based on ECGs and cardioversion) and without presence of
AF/AFL as a stratiﬁcation factor. The time between recurrence
and CV hospitalization/death was signiﬁcantly reduced by
dronedarone [hazard ratio (HR) (95% CI) ¼ 0.771 (0.643–
0.925), P ¼ 0.0048].
The Nelson–Aalen cumulative incidence of all CV and non-CV
hospitalizations is shown in Figure 3A. Repeated CV hospitalizations
were reduced with dronedarone, but non-CV hospitalizations
were not. Figure 3B shows the hospitalization burden (cumulative
incidence of hospitalizations) of CV and non-CV hospitalization
during the ﬁrst 2 years after randomization. The hospitalization
burden for CV hospitalization decreased over time and remained
lower with dronedarone treatment.
The HR estimates and 95% CIs for the primary endpoint and
time to ﬁrst CV hospitalization events are shown in Figure 4 for
the different regions. Results were consistent with the overall
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Table 3 Duration of ﬁrst hospitalization during the on-study period according to the level of care
Placebo
(n 5 2327)
Dronedarone
(n 5 2301)
P value
All CV hospitalizations
Patients with at least one CV hospitalization 859(36.9%) 675(29.3%)
Total number of nights 5807 4792 ,0.001
Nights in intensive care/coronary care unit 888 482 0.027
Nights in step-down unit or medium care 922 724 0.010
Nights on regular ward 3997 3586 0.002
AF hospitalizations
Patients with at least one AF hospitalization 510(21.9%) 335(14.6%)
Total number of nights 2837 2092 ,0.001
Nights in intensive care/coronary care unit 358 175 0.007
Nights in step-down unit or medium care 518 292 ,0.001
Nights on regular ward 1961 1625 ,0.001
................................................................................
Table 4 Survival analysis: time from randomization to
ﬁrst CV hospitalization in intensive care/coronary care
unit during the study period
Placebo
(n 5 2327)
Dronedarone
(n 5 2301)
Number of events 270 (11.6%) 218 (9.5%)
Cumulative incidence
of events (95% CI)
At 6 months 0.057 (0.047–0.066) 0.041 (0.033–0.050)
At 1 year 0.082 (0.071–0.094) 0.068 (0.058–0.079)
At 2 years 0.127 (0.112–0.142) 0.107 (0.093–0.121)
Log-rank test P value 0.0174
HR (95% CI)
a 0.806 (0.674–0.963)
aDetermined from Cox regression model.
C. Torp-Pedersen et al. 1122population, with all risk estimates favouring dronedarone treat-
ment (P value for interaction¼0.62). Although the duration of
CV hospitalizations varied across regions according to regional
clinical habits, the effect of dronedarone on the reduction of CV
hospitalizations was consistent across regions, as shown in
Figure 4B (P ¼ 0.48).
Discussion
The main ﬁnding of this ATHENA post hoc analysis is that drone-
darone reduces the number of CV hospitalizations and reduces
the length of hospital stay for CV reasons. The reduction in
ﬁrst hospitalizations in intensive care/cardiac care units suggests
a reduction in CV hospitalizations associated with potentially life-
threatening conditions. Since CV hospitalization is a valid surro-
gate endpoint for mortality in studies of AF,
10 this is an impor-
tant ﬁnding. The overall reduction of hospitalization burden
observed in the current analysis, including reduction of CV
events, indicates that dronedarone may reduce the severity of
CV disease in this patient population.
Anti-arrhythmic drugs approved for maintenance of sinus
rhythm in patients with AF have all been documented to prevent
or delay the recurrence of AF.
13 ATHENA is the only study
powered to demonstrate a clinical beneﬁt beyond maintenance
of sinus rhythm speciﬁcally in patients with AF.
A post hoc analysis of the AF Follow-up Investigation of Rhythm
Management (AFFIRM) study also investigated CV hospitalization
as an alternative endpoint for death.
14 In that analysis, patients
treated with a rhythm-control strategy were hospitalized for CV
reasons at a higher rate than patients treated with a rate-control
strategy (46 vs. 36%, P , 0.001). However, when hospitalizations
related to treatment (i.e. cardioversion) were excluded, rates were
similar in both cohorts (24 vs. 27%, respectively). A further analysis
ofthedatafoundsigniﬁcantassociationsbetweenCVhospitalization
and death in both treatment arms.
14
The AF–CHF study was conducted in a patient population with
more and worse heart failure than either ATHENA or AFFIRM, but
the hospitalization results of AF–CHF were similar to those of
AFFIRM.
15 Patients in the rhythm-control cohort were hospitalized
Figure 3 Incidence of cardiovascular and non-cardiovascular hospitalizations. (A) Summary of Nelson–Aalen cumulative incidence curves of
all cardiovascular and non-cardiovascular hospitalizations during the on-study period (intention-to-treat population); (B) curve and summary of
cumulative incidence difference between each time point for all cardiovascular and non-cardiovascular hospitalizations during the on-study
period (intention-to-treat population).
Figure 2 Kaplan–Meier cumulative incidence curves of time
from ﬁrst atrial ﬁbrillation/atrial ﬂutter recurrence (based on
electrocardiograms and cardioversion) to ﬁrst cardiovascular
hospitalization during the on-study period. Data are for all ran-
domized patients with a ﬁrst atrial ﬁbrillation/atrial ﬂutter recur-
rence and without presence of atrial ﬁbrillation/atrial ﬂutter as
per stratiﬁcation factor.
Effect of dronedarone on hospitalizations 1123at signiﬁcantly higher rates during the 1 year than patients in the
rate-control cohort (46 vs. 39%, respectively; P ¼ 0.001). Further-
more, hospitalizations for AF were signiﬁcantly higher in the
rhythm-control cohort than the rate-control cohort (14 vs. 9%,
respectively; P ¼ 0.001).
Althoughareductioninhospitalizationswasalsodemonstratedin
patients with AF for dofetilide in the two Danish Investigations of
Arrhythmias and Mortality ON Dofetilide (DIAMOND),
16 the
primary populations of those studies were patients with heart
failure or recent myocardial infarction. A pooled post hoc analysis
of the 506 patients with AF at baseline in the DIAMOND studies
demonstrated a reduction in hospitalizations with dofetilide treat-
ment, accompanied by a more frequent conversion to sinus
rhythm.
16
The reduced number and duration of hospitalizations in the
dronedarone group vs. placebo seen in the current ATHENA
analysis may also be related to maintenance of sinus rhythm. In
accordance with this ﬁnding, hospitalizations related to AF
were markedly reduced in number and duration. This reduction
in AF-related hospitalizations was not simply due to fewer
cardioversions, but also to a decrease in the severity of recurrent
AF episodes.
It is also noteworthy that hospitalizations related to acute cor-
onary syndromes were reduced. While hospitalizations related
to acute coronary syndromes could be reduced by less frequent
AF, one might speculate that the heart-rate-lowering effect of dro-
nedarone may be important. Dronedarone slows the heart rate
not only during AF but also during sinus rhythm.
17 This may be
the result of a class IV effect; however, like the benzocycloalkane
ivabradine, dronedarone has been shown to inhibit the If-current
of the sinus node, inducing a selective reduction in heart
rate.
18,19 The potential importance of heart rate lowering has
recently been strengthened by the results of the Systolic Heart
failure treatment with the If inhibitor ivabradine Trial (SHIFT),
where the heart-rate-lowering effect of ivabradine reduced CV
mortality in patients with heart failure.
20
Although the number of hospitalizations due to acute coronary
syndrome and AF was signiﬁcantly reduced by dronedarone, hos-
pitalizations due to other CV causes were not signiﬁcantly different
from placebo. There was a noticeable trend towards reduced
Figure 4 Hazard ratio (dronedarone 400 mg bd vs. placebo) estimates with conﬁdence intervals according to region. (A) Primary endpoint
(ﬁrst cardiovascular hospitalization or death from any cause); (B) cardiovascular hospitalization. Data are for all randomized patients.
aDeter-
mined from Cox regression model.
bP values are for interaction between regions and treatment based on Cox regression model.
C. Torp-Pedersen et al. 1124hospitalization days due to stroke in the dronedarone group (439
vs. 1122 in the placebo group), and although this was not signiﬁcant
(P ¼ 0.079), possibly due to the small number of patients hospital-
ized due to stroke (43 dronedarone patients vs. 61 placebo
patients), it nevertheless provides additional support for the
beneﬁts of dronedarone treatment in this patient population. Inter-
estingly, a previous ATHENA subanalysis that took into account
not only hospitalizations due to stroke, but also death due to
stroke, and strokes reported only as AEs, demonstrated that the
incidence of stroke was signiﬁcantly reduced with dronedarone
treatment, from 1.8% per year with placebo to 1.2% per year
[HR ¼ 0.66 (95% CI 0.46–0.96), P ¼ 0.027].
21
In this post hoc analysis, the data for the six regions for the
primary outcome and for CV hospitalizations alone were consist-
ent with the overall study population.
It should be noted that the results of the current study cannot
be extrapolated to other anti-arrhythmic drugs. In the
meta-analysis by Lafuente-Lafuente,
22 although the efﬁcacies of
commonly used anti-arrhythmic drugs appeared similar, there
were some speciﬁc differences between them, which could
result in important differences in outcomes for patients. Flecainide
and propafenone do not lower heart rate and may thereby be less
efﬁcacious in reducing hospitalizations. Sotalol has a dual effect of
being a beta-blocker and a class III anti-arrhythmic drug, but it may
cause torsades de pointes tachycardia and it had an uncertain
safety proﬁle in the meta-analysis. Amiodarone appeared to be
the most effective of the drugs evaluated by Lafuente-Lafuente in
preventing recurrences of AF, while producing fewer AEs and
having less associated mortality than beta-blockers.
22 In compari-
son with dronedarone, amiodarone may be more efﬁcacious for
maintenance of sinus rhythm,
23 but it has a poorer side-effect
proﬁle, particularly with long-term use.
In conclusion, treatment of patients with paroxysmal or persist-
ent AF or AFL with dronedarone is associated with a marked
reduction in the number and duration of CV hospitalizations, par-
ticularly those associated with potentially life-threatening
conditions.
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